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Abstract
 
Monocytes recruited from the blood are key contributors to the nature of an immune re-
sponse. While monocyte recruitment in a subset of immunopathologies has been well studied
and largely attributed to the chemokine monocyte chemoattractant protein (MCP)-1, mecha-
nisms mediating such recruitment to other sites of inflammation remain elusive. Here, we
showed that localized inflammation resulted in an increased binding of monocytes to perifolli-
cular high endothelial venules (HEVs) of lymph nodes draining a local inflammatory site.
Quantitative PCR analyses revealed the upregulation of many chemokines in the inflamed
lymph node, including MCP-1 and MIG. HEVs did not express detectable levels of MCP-1;
however, a subset of HEVs in inflamed lymph nodes in wild-type (but not tumor necrosis fac-
tor [TNF] null mice) expressed MIG and this subset of HEVs preferentially supported mono-
cyte binding. Expression of CXCR3, the receptor for MIG, was detected on a small subset of
peripheral blood monocytes and on a significant percentage of recruited monocytes. Most im-
portantly, in both ex vivo and in vivo assays, neutralizing anti-MIG antibodies blocked mono-
cyte binding to inflamed lymph node HEVs. Together, these results suggest that the lymph
node microenvironment can dictate the nature of molecules expressed on HEV subsets in a
TNF-dependent fashion and that inflammation-induced MIG expression by HEVs can medi-
ate monocyte recruitment.
Key words: HEV • cell adhesion • microenvironment • homing • lymph node
 
Introduction
 
One of the first cell types to arrive at a site of inflammation
is the blood monocyte. It has long been known that
monocytes can differentiate into tissue macrophages,
which in turn have phagocytic and antigen presentation
capabilities. It is also known that monocytes can differenti-
ate into dendritic cells (1, 2). Monocytes, themselves, and
the cells they differentiate into produce a host of cytokines
and chemokines and thus, in large part, dictate the cell
types that are subsequently recruited to an inflammatory
site. Thus, both by virtue of the cytokines they produce
and by virtue of the cell types they differentiate into upon
entering the tissue, monocytes recruited from the blood
are key orchestrators of the nature of an immune response.
While monocytes are critical to mounting an effective im-
mune response, their presence in chronic inflammatory
sites can be pathogenic. For example, monocyte recruit-
ment is an initiating event in the advent of atherosclerotic
lesions (for reviews, see references 3–5).
Chemokines are a class of cytokines with chemoattrac-
tant properties, as well as other functions. Several chemo-
kines are capable of chemoattracting monocytes in vitro and,
of these, monocyte chemoattractant protein (MCP)
 
*
 
-1 is
among the most potent (6). Furthermore, MCP-1 and its
receptor, CCR2, are found in atherosclerotic lesions (7, 8).
Deleting genes for either MCP-1 or CCR2 attenuates the
incidence of lesions in established models of atherosclerosis
(9, 10) and appears to do so by blocking the recruitment of
monocytes. More recently, MCP-1 and CCR2 have also
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EAE, experimental autoimmune encepha-
lomyelitis; HEV, high endothelial venule; MCP, monocyte chemoattrac-
tant protein; PNAd, peripheral node addressin. 
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been implicated in the development of inflammatory le-
sions of experimental autoimmune encephalomyelitis
([EAE] references 11–13). Although monocyte recruitment
in atherosclerosis and EAE has been well studied and
largely attributed to the CC chemokine MCP-1, mecha-
nisms mediating such recruitment to many other sites of
inflammation remain elusive.
Leukocyte recruitment to and through the lymph node
is critical to immune surveillance and to mounting an ef-
fective immune response. Leukocytes enter the lymph
node via two routes: the afferent lymphatics (from the tis-
sue) or the specialized endothelium, the high endothelial
venules ([HEVs] from the blood). Leukocyte recruitment
to the HEVs has been well studied (14, 15). The required
molecular mechanisms, both adhesion molecules and che-
mokines and their receptors, orchestrating recruitment of
naive T cells to lymph nodes have been largely defined
(16–18). As has been shown previously, upon acute inflam-
mation in the footpad, there is a selective increase in re-
cruitment of monocytes to HEVs in the draining lymph
node (19). The mechanisms mediating monocyte-selective
recruitment in this setting are unknown. Here we exam-
ined the potential role of chemokines in mediating mono-
cyte-selective increase in recruitment to HEVs in inflamed
lymph nodes. Since TNF has been shown to be upstream
of chemokine expression (20–22), the chemokine expres-
sion patterns and monocyte binding capability of inflamed
lymph nodes from TNF null mice were also examined.
We show that whereas MCP-1 may be critical in mono-
cyte recruitment in other systems, we were unable to dem-
onstrate expression of this molecule on HEVs in normal or
inflamed lymph nodes. Thus, MCP-1 expression cannot ac-
count for the recruitment observed, at least at the level of
adhesion to the HEVs. Interestingly, HEVs display the CXC
chemokine MIG in response to an inflammatory stimulus
and this subset of HEVs has an enriched capacity to bind
monocytes. In TNF null mice, the increase in the number
of HEVs expressing MIG is not observed upon induction of
inflammation, nor is there an increase in monocyte binding
to HEVs, as seen in wild-type mice. Furthermore, function-
perturbing antibodies to MIG block monocyte binding in
both in vivo and ex vivo assay systems. Together, these re-
sults suggest that the lymph node microenvironment can
dictate the nature of molecules expressed on HEV subsets in
a TNF-dependent fashion and that MIG can mediate
monocyte binding in an inflammatory response.
 
Materials and Methods
 
Footpad Injection and Isolation of Lymph Nodes.
 
C57BL/6 mice
(2–3 mo old) were obtained from The Jackson Laboratory; age
and sex-matched TNF
 
 
 
/
 
 
 
 mice (on a C57BL/6 background;
reference 23) were bred in house. At day 0, mice (10–12 per
group) were briefly anesthetized with isoflurane and 40 
 
 
 
l of
complete Freund’s adjuvant (5881; Sigma-Aldrich) was injected
subcutaneously into the footpad of the forepaw through a 27-
gauge needle. At day 3 (
 
 
 
72 h after injection), mice were killed
and brachial lymph nodes were harvested. Brachial lymph node–
draining footpads that were not inflamed were also harvested. All
animal work was approved by an internal review board and met
NIH Institute Animal Care and Use Committee standards.
Lymph nodes were either snap-frozen for subsequent RNA iso-
lation or embedded in O.C.T. Compound (4583; Tissue-Tek)
for sectioning.
 
Real-Time Quantitative PCR (TaqMan™).
 
Total RNA was
extracted using RNA Stat 60 according to the manufacturer’s
instructions (CS110; Tel-Test). Total RNA was treated with
DNase I (776-785; Roche Laboratories) to eliminate possible
genomic DNA contamination. Total RNA was then reverse
transcribed with oligo(dT)14–18 (18418; Life Technologies),
random hexamers (C1181; Promega), dNTPs (27-2035; Amer-
sham Pharmacia Biotech), and Superscript II (18064-014; Life
Technologies), according to the manufacturer’s instructions. 50
ng of cDNA was amplified using 12.5 
 
 
 
l of TaqMan™ universal
master mix (PerkinElmer), 0.2 
 
 
 
M of gene-specific TaqMan™
probe, and 0.9 
 
 
 
M of gene-specific forward and reverse primers
in a final volume of 25 
 
 
 
l. Primers and probes specific to each
chemokine tested (see Fig. 1) were obtained from PerkinElmer.
Ubiquitin mRNA levels were used to normalize between sam-
ples. Gene-specific PCR products were measured at each cycle,
through 40 cycles, by means of a GeneAmp 5700 Sequence De-
tection System (PerkinElmer). mRNA levels were quantitated
by comparing experimental levels to standard curves generated
using serial dilutions of plasmids containing the chemokine gene
being evaluated.
 
Immunohistochemistry.
 
Primary antibodies that recognize the
following antigens were used at the listed concentrations: B220
(10 
 
 
 
g/ml 01129A; BD PharMingen), peripheral node addressin
([PNAd] BD PharMingen) (15 
 
 
 
g/ml 09961D), CD11b (10 
 
 
 
g/
ml M030055; BD PharMingen), 6CKine (CCL21; R&D Sys-
tems) (20 
 
 
 
g/ml BAF457), IP10 (30 
 
 
 
g/ml CXCL10; made in
house), MCP-1 (CCL2; R&D Systems) (30 
 
 
 
g/ml BAF479),
and MIG (CXCL9; R&D Systems) (20 
 
 
 
g/ml AF-492-NA and
BAF492). 10-
 
 
 
m frozen sections were fixed in 2% paraformalde-
hyde for 10 min, blocked in PBS/2% BSA, and then incubated
with primary antibodies for 1 h at room temperature. With the
exception of the antibodies against B220 and CD11b, which
were fluorescently conjugated, secondary antibodies were used at
a 1:100 dilution for 30 min at room temperature. After appropri-
ate secondary blocking, sections were then stained with a tertiary
antibody. Antibodies to MCP-1 and IP10 were incubated with
sections before fixation. In some cases, anti-MIG antibodies were
injected in vivo and detected ex vivo using a FITC-conjugated
secondary antibody. Stained sections were visualized under a flu-
orescent confocal microscope (Leica TCS SP).
 
In Vivo “Snapshot” Assay.
 
5-
 
 
 
m sections of lymph nodes
were fixed in acetone at 
 
 
 
20
 
 
 
C for 5 min, blocked in PBS/2%
BSA, and subjected to double-indirect immunohistochemistry
for PNAd and CD11b as described previously. Sections were vi-
sualized under a fluorescent microscope. All PNAd
 
 
 
 vessels from
10 lymph nodes were counted and scored for the presence of at
least one CD11b-bright cell. Percentage of HEVs with bound
monocyte was calculated as (number of PNAd
 
 
 
 vessels with asso-
ciated CD11b-bright cell/total number of PNAd
 
 
 
 vessels 
 
 
 
100).
 
In Vivo Blocking Studies.
 
Inflammation was induced in foot-
pads of forepaws, as described previously. 20 h before killing, 1
mg of antibody (either anti-MIG; R&D Systems, lot AGS01) or
control (AB-108-C; R&D Systems) was injected intraperito-
neally per mouse. At day 3 after induction of inflammation, mice
were killed and brachial lymph nodes harvested and embedded
for sectioning as described previously. Sections were either 
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stained with a FITC-conjugated secondary (anti–goat) antibody
to localize injected primary antibody or subjected to the in vivo
snapshot assay.
 
Ex Vivo HEV Binding Assay.
 
A modification of the Stamper-
Woodruff assay (24) was performed as follows. T cells were iso-
lated from peripheral lymph nodes of Balb/c mice and WEHI 78/
24 cells were subcultured to be in plateau phase at the time of the
experiment. T cells and WEHI 78/24 cells were mixed in a 1:1 ra-
tio (final concentration of 10
 
7
 
cells per milliliter) in binding buffer
(DMEM supplemented with 20 mM Hepes and 1% BSA, pH 6.9).
100 
 
 
 
l of the cell suspension was placed on each of four 10-
 
 
 
m
frozen sections of lymph nodes (per condition) that had been cir-
cled using a hydrophobic slide marker (2 cm diameter). Slides were
immediately placed on a rotating platform (70 rpm) at 4
 
 
 
C for 30
min. Slides were then fixed in ice cold PBS/2% glutaraldehyde.
Preliminary experiments had shown that T cells bind uninflamed
and inflamed HEVs equivalently (data not shown); therefore, T
cells were used as an internal standard. WEHI 78/24 and T cells
(distinguished by an extreme size difference) bound to the lymph
node HEVs were counted under a phase microscope. 100 HEVs
were counted, for each condition, over several lymph nodes and
across four sections. Data is presented as WEHI 78/24 binding rel-
ative to the internal standard T cells. Data is normalized such that
the WEHI 78/24:T cell ratio for uninflamed lymph node HEVs is
set at 1 for all experiments. For antibody blocking experiments,
sections were incubated at 4
 
 
 
C with blocking antibody (50 
 
 
 
g/ml)
or control for 10 min before the addition of cells. Antibody re-
mained present for the duration of the experiment.
 
FACS
 
®
 
 Analysis.
 
Balb/c mice (Taconic) were given a single
intraperitoneal injection of 3 ml thyoglycollate (T-9032; Sigma-
Aldrich). 2 d later, peritoneal cells were harvested using perito-
neal lavage with 10 ml HBSS (BW04-315Q; Biowhittaker). The
cells were counted, washed, and resuspended to 10
 
6
 
 cells per mil-
liliter in staining buffer: HBSS containing 2% FBS (BW14-501F;
Biowhittaker) and 10 mM Hepes (17-737E; Biowhittaker). To
block nonspecific staining, cells were incubated with 50 
 
 
 
g/ml
rat IgG (I8015; Sigma-Aldrich) and Fc block (BD PharMingen)
for 30 min at 4
 
 
 
C. Cells were subsequently incubated for 30 min
at 4
 
 
 
C with either a biotin-conjugated rat anti–mouse CXCR3
mAb (LM22.23.17; DNAX) or a biotin-conjugated isotype con-
trol rat IgG2b (11182C; BD PharMingen) in staining buffer con-
taining 50 
 
 
 
g/ml nonspecific rat IgG (to block nonspecific bind-
ing of Ig). Cells were washed and stained for 30 min at 4
 
 
 
C with
FITC-conjugated anti–mouse CD11b, PE anti–mouse F4/80, or
APC anti–mouse GR1 (BD PharMingen) plus cychrome-strepta-
vidin. Cells were washed a final time, resuspended in staining
buffer, and analyzed on a FacsCalibur™ (Becton Dickinson). PB-
MCs were isolated from normal human donors, incubated with
Fc block plus 50 mg/ml mouse IgG (Becton Dickinson) for 30
min at 4
 
 
 
C, and subsequently stained with FITC-conjugated anti-
CXCR3 (R&D Systems) or FITC-conjugated mouse IgG1, an
isotype matched negative control (R&D Systems), APC-conju-
gated anti-CD14 (BD PharMingen), PE-conjugated anti-CD11c
(BD PharMingen), and cychrome-conjugated anti-CD4 and anti-
CD8 (BD PharMingen).
 
Results
 
The CXC Chemokine MIG (CXCL9) Is Upregulated at the
mRNA Level in Inflamed Lymph Nodes.
 
MCP-1/CCL2
appears to be critical for the recruitment of monocytes in
atherosclerosis and EAE. To determine whether MCP-1
contributes to recruitment of monocytes to HEVs in in-
flamed lymph nodes we measured the MCP-1 (as well as
other chemokines known to chemoattract monocytes) in
normal lymph nodes and lymph nodes draining a local in-
flammation using real-time quantitative PCR (TaqMan™;
Figure 1. Real-time quantitative PCR (TaqMan™) analyses of chemokine expression in
lymph nodes. Total RNA was isolated from pools of lymph nodes draining inflamed footpads
(black bars) and pools of lymph nodes draining the contralateral footpads that were not inflamed
(Normal, white bars). Real-time quantitative PCR was performed on 50 ng of reverse-tran-
scribed cDNA using primers that specifically recognize a panel of chemokines. (A) mRNA lev-
els for the subset of chemokines known to chemoattract monocytes in vitro and for MIG are
shown. Data is expressed as fg per 50 ng cDNA. With the exception of RANTES, there was a
relative increase in all the chemokines known to chemoattract monocytes, upon inflammation.
P value   0.005. Additionally, there was a greater than ninefold increase in the mRNA levels of
MIG. (B) mRNA levels for a subset of chemokines in normal (not inflamed) and inflamed
lymph nodes from TNF null mice are shown. 
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Fig. 1). Total RNA was isolated from pools of lymph
nodes draining inflamed footpads and pools of lymph nodes
draining the contralateral footpads that were not inflamed.
Real-time quantitative PCR was performed on 50 ng of
reverse-transcribed cDNA using primers that specifically
recognize a panel of chemokines. mRNA levels for the
subset of chemokines known to chemoattract monocytes in
vitro and for MIG are shown in Fig. 1 A. With the excep-
tion of regulated on activation, normal T cell expressed and
secreted (RANTES; CCL5), there was a relative increase
in all the chemokines known to chemoattract monocytes
(including MCP-1), upon inflammation in wild-type mice.
Additionally, there was a greater than ninefold increase in
the mRNA levels of MIG (from 12 fg/50 ng cDNA to 115
fg/50 ng cDNA), a chemokine which has not previously
been shown to chemoattract monocytes.
TNF has been shown to play a key role in expression of
many chemokines (20, 21); therefore, the role of TNF in
induction of MIG was examined in TNF null mice. Failure
of TNF null mice to upregulate TNF upon inflammation
was confirmed by real-time quantitative PCR (data not
shown). Examination of chemokine expression in TNF
null lymph nodes before and after inducing inflammation
revealed that whereas basal expression of a subset of
chemokines was decreased relative to wild-type mice, con-
firming published reports (21), chemokine expression in
inflamed lymph nodes of TNF null mice was upregulated
to levels similar to those of wild-type lymph nodes. Exam-
ples of this are shown in Fig. 1 B.
 
Upon Inflammation, Recruitment of Monocytes to Lymph
Node HEVs Is Increased in Wild-Type Mice, but not in TNF
Null Mice.
 
We quantitated the increased monocyte re-
cruitment across lymph node HEVs upon inflammation us-
ing an in vivo “snapshot” assay (Fig. 2). 3 d after inducing
inflammation, lymph nodes draining either inflamed foot-
pads or footpads that were not inflamed were embedded
in O.C.T. and sectioned. Double-indirect immunohis-
tochemistry was performed to identify HEVs (PNAd
 
 
 
, red;
Fig. 2 inset) and monocytes (CD11b-bright, green). These
CD11b-bright cells are positive for CD68 and negative for
CD3, CD19, and NK1.1 (data not shown). HEVs were
counted and scored for the presence or absence of bound
monocytes at the time of sacrifice and percentage of total
HEVs with one or more monocytes bound was calculated.
Induction of inflammation in the footpads of wild-type
mice results in nearly a threefold increase in monocyte re-
cruitment to lymph node HEVs (from 6 to 16%; Fig. 2).
As TNF has been shown to be upstream of chemokine ex-
pression, we asked whether TNF null mice demonstrated
an equivalent ability to recruit monocytes. Also shown in
Fig. 2, TNF null mice have a reduced ability to recruit
monocytes to HEVs upon inflammation, compared with
wild-type mice.
 
MIG Protein Is Expressed on a Subset of HEVs in Wild-
Type Lymph Nodes.
 
While real-time quantitative PCR
had indicated that a number of known monocyte chemoat-
tractants were up-regulated upon inflammation in the
lymph node at the mRNA level, the protein localization of
these chemokines within the lymph node remained un-
clear. Based on the dominant role MCP-1 plays in mono-
cyte recruitment in atherosclerosis, we expected that
MCP-1 would be expressed prominently on HEVs. We also
speculated that IP10 might be expressed on the HEVs,
given that its mRNA induction was amongst the highest of
the known monocyte chemoattractant chemokines (Fig. 1 A).
Serial sections of inflamed lymph nodes were subjected
to double-indirect immunohistochemistry (Fig. 3 A). On
all sections, an antibody against the B cell marker B220 was
used to illuminate the B cell follicles for orientation. Serial
sections were stained with antibodies against PNAd to
identify HEVs, IP10, MCP-1 or an isotype control. While
both MCP-1 and IP10 were highly expressed in macro-
phage-rich areas, to our surprise neither was displayed on
HEVs (Fig. 3 A).
Because MIG was strongly induced upon inflammation
at the mRNA level, we examined its protein expression as
well (Fig. 3 B). Two staining methods were used. In the
right panel, serial frozen-sections were stained with directly
conjugated anti-6Ckine and anti-MIG antibodies and ana-
lyzed by confocal microscopy. The B cell follicle is out-
lined (based on B220 staining in a serial section). MIG was
expressed on a subset of 6CKine
 
 
 
 HEVs close to the B cell
follicle/T cell border. 6Ckine
 
 
 
MIG
 
 
 
 HEVs were observed
in the T cell zone and 6Ckine
 
 
 
MIG
 
 
 
 HEVs were ob-
served in the perifollicular area. Some HEVs (an example is
indicated by the white arrow) show colocalization of
6Ckine and MIG (seen as yellow). The yellow arrow indi-
Figure 2. Recruitment of monocytes to lymph node HEVs is increased
in wild-type mice, but not in TNF null mice, upon inflammation. 3 d af-
ter inducing inflammation, lymph nodes draining either inflamed foot-
pads (black bars) or footpads that were not inflamed (white bars) were
embedded in O.C.T., sectioned and subjected to the snapshot assay.
Double-indirect immunohistochemistry was performed to identify all
HEVs (red; see inset) and monocytes (green). The data is presented as
percentage of total HEVs with at least one bound monocyte. Inducing in-
flammation in the footpads of wild-type mice results in nearly a threefold
increase in monocyte recruitment to lymph node HEVs. TNF null mice
have a reduced ability to recruit monocytes to HEVs upon inflammation,
compared to wild-type mice. This experiment was repeated four times for
wild-type mice and three times for TNF null mice. P value   0.05. 
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Figure 3. MIG expression on HEVs is correlated with increased monocyte-
selective recruitment.   (A) Serial sections of lymph nodes draining inflamed foot-
pads were stained with antibodies against PNAd (top left panel, green) to identify
HEVs, IP10 (top right panel, green), MCP-1 (bottom left panel, green), or an
isotype control (bottom right panel, green). On all sections, an antibody against
the B-cell marker B220 (red) identified the follicles and was used for orientation.
MCP-1 and IP10 was not displayed on HEVs, but rather in macrophage-rich ar-
eas. (B) Serial sections (left and middle panels) were stained with either antibodies
against PNAd (left panel, green) and B220 (left panel, red) or MIG (middle
panel, green) and 6CKine (middle panel, red). MIG was expressed on a subset of
6CKine  HEVs. White arrows pair vessels between left and middle panels; yel-
low arrow indicates a vessel that is absent in the section represented in the middle
panel. The right panel depicts vessels that were stained in vitro for 6CKine (red)
and MIG (green). The outline depicts the B cell follicle border. Arrows depict
vessels in which expression is completely colocalized (white) or partially colocal-
ized (yellow). (C) Serial sections of lymph nodes draining inflamed footpads were
stained for PNAd (left panels, green) and CD11b (red) or MIG (right panels, green) and CD11b (red). MIG  HEVs showed a higher association with
monocytes than MIG  HEVs (arrows indicate MIG  vessels). (D) Serial sections were stained with antibodies against PNAd and MIG. The number of
PNAd  and MIG  vessels was then counted across 10 lymph nodes. Data is presented as the percentage of total HEVs that were MIG . Lymph nodes
that were not inflamed (white bar) had  2% MIG  HEVs. Upon inflammation (black bar), the number of MIG  HEVs increased to  12%. This exper-
iment was repeated twice. (E) Immunohistochemistry was performed as shown in C. All PNAd  (total HEVs) and MIG  vessels were counted and
scored for whether a monocyte was bound. Data is presented as percentage of HEV  for at least one bound monocyte. Upon inflammation (black bars)
this increased from  6% in lymph nodes that were not inflamed (white bar) to  20%. The percentage of the subpopulation of total inflamed HEVs that
were MIG  and had a bound monocyte was  60%; whereas, the percentage of the MIG  HEV subpopulation that had a bound monocyte was only
13%. This experiment was repeated twice. 
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cates an HEV when showed colocalization of MIG and
6Ckine staining in the region closer to the follicle and less
MIG staining further away from the follicle. There are sev-
eral HEVs that are 6Ckine
 
 
 
 and MIG
 
  
 
as well. Thus, MIG
is expressed on a subset of 6Ckine
 
 
 
 vessels, predominantly
in the perifollicular region of the lymph node. MIG was
also expressed in macrophage-rich areas (data not shown).
In a second set of experiments, unconjugated anti-MIG an-
tibody was injected into mice at the same concentrations
used for the blocking experiments and after killing (2 h af-
ter injection) the distribution of the injected antibody was
illuminated using FITC-labeled secondary antibody and
HEVs were identified by staining with anti-6Ckine anti-
body. Interestingly, as shown in the middle panel of Fig. 3
B, the injected MIG antibody has localized to the HEVs
but appears to be basolateral to the 6Ckine staining.
 
The Percentage of HEVs that Express MIG Protein Is In-
creased upon Inflammation in Wild-Type Mice.
 
On gross ex-
amination of sections from inflamed and uninflamed lymph
nodes stained with an antibody against MIG, it was appar-
ent that the number of HEVs that expressed MIG was in-
creased upon inflammation. To quantitate this observation,
serial sections were stained with antibodies to PNAd and to
MIG and the percentage of MIG
 
  
 
HEVs was calculated. As
shown in Fig. 3 D, there is a striking (sixfold) increase in
the percentage of HEVs that express MIG in inflamed
lymph nodes compared with resting lymph nodes. Interest-
ingly, there was no induction of MIG
 
 
 
 HEVs in TNF null
mice; the percentage of MIG
 
 
 
 
 
HEVs in both normal and
inflamed lymph nodes was similar to that of uninflamed
wild-type mice.
 
The Subset of HEVs that Express MIG has an Enriched Ca-
pacity for Binding Monocytes.
 
Many of the HEVs that are
capable of supporting monocyte binding are found in the
peri-B cell follicle region of the lymph node, the same re-
gion in which MIG
 
 
 
 HEVs are observed. Therefore, we
asked whether HEVs that express MIG have an enriched
capacity to bind monocytes using the in vivo snapshot as-
say. Serial sections were stained for PNAd, MIG, and
monocyte markers (Fig. 3 C) and all PNAd
 
 
 
 and MIG
 
 
 
vessels were scored for their capacity to bind monocytes.
Indeed, the MIG
 
 
 
 
 
subpopulation of HEVs has a dramati-
cally increased capacity to bind monocytes compared with
MIG
 
  
 
HEVs and total HEVs (Fig. 3 E).
 
A Function-perturbing Antibody to MIG Blocks Monocyte
Binding to Inflamed HEVs In Vivo.
 
The correlation of
MIG expression and monocyte binding is compelling;
however, in order to determine whether there is a func-
tional significance to this, we asked whether a function-
perturbing anti-MIG antibody was able to block monocyte
recruitment. For these experiments, mice that had received
an inflammatory regimen were treated intraperitoneally
with either control or anti-MIG antibodies.
To confirm that the antibodies reached and bound the
HEVs, sections were stained with a FITC-conjugated sec-
ondary antibody to localize the intraperitoneally injected
Figure 4. A function-perturbing antibody to
MIG blocks monocyte binding to inflamed HEVs
in vivo.   To test whether MIG plays a role in
monocyte recruitment to inflamed lymph nodes in
vivo, inflammation was induced in both forepaws
of 12 mice. The mice were divided into two
groups, each receiving either a function-perturbing
antibody to MIG or a control antibody intraperito-
neally. In one experiment (Exp. 2), 12 mice that
were not inflamed (white bars) also received the
antibody treatment. Draining lymph nodes were
isolated and sectioned. (A) To confirm that the an-
tibodies reached and bound the HEVs, sections
were stained with a FITC-conjugated secondary
antibody to visualize the intraperitoneally injected
antibody. Sections were costained with an antibody
against B220. The neutralizing antibody to MIG
localized to the HEV (right, green).   (B) The in
vivo snapshot assay was performed to determine the
percentage of HEVs with a bound monocyte in the
presence of either a MIG neutralizing antibody
( MIG) or the control (Cont Ab). 15–20% of in-
flamed HEVs had a bound monocyte in the pres-
ence of the control antibody, similar to what was
observed in the absence of antibody (compare No
Ab to Cont Ab, black bars). In the presence of a
MIG neutralizing antibody this percentage was re-
duced to levels equivalent to uninflamed controls
(white bars). 
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antibody. As shown in Fig. 4 A, the neutralizing antibody
to MIG (but not the control antibody) localized to the
HEVs (right panel, green) confirming display of MIG on
the HEVs and presence of neutralizing antibody during the
peak of monocyte recruitment.
The ability of HEVs to support monocyte binding in the
presence of anti-MIG or control antibody was evaluated in
two independent in vivo snapshot assays shown in Fig. 4 B.
Due to limited amounts of neutralizing antibody, in one as-
say only mice receiving the inflammatory regimen were
treated with control and anti-MIG antibody whereas both
control and inflamed mice were included in the second ex-
periment. In both cases, the percentage of HEVs able to
support monocyte binding in the presence of control anti-
body was 
 
 
 
15–20%, in complete agreement with previous
data. Strikingly, in both experiments, the presence of neu-
tralizing anti-MIG antibody reduced monocyte binding to
background levels. These results suggest that MIG plays a
role in the recruitment of monocytes to inflamed HEVs.
 
Upon Inflammation, Binding of Monocytes to Lymph Node
HEVs Ex Vivo Is Increased in Wild-Type Mice, but not in
TNF Null Mice.
 
In the in vivo assay, the anti-MIG block-
ade was in place for a significant period during the peak of
monocyte recruitment to the inflamed lymph nodes open-
ing up the possibility that MIG may be acting directly or
indirectly. The Stamper-Woodruff frozen section ex vivo
staining assay offers an excellent approach to study mole-
cules presented on HEVs and their role in cell recruitment
(24). We used this model to look at the ability of HEVs to
bind a monocyte cell line, WEHI 78/24.
Local inflammation resulted in a selective increase in
WEHI 78/24 binding capacity of HEVs analogous to the
in vivo results. As shown in Fig. 5 A, lymph nodes from
inflamed wild-type mice had a twofold increase in WEHI
78/24 binding to HEVs when compared with mice that
were not inflamed. Furthermore, WEHI 78/24 binding to
inflamed HEVs from TNF null mice was similar to that
observed in uninflamed wild-type mice, also analogous to
what was observed in vivo, suggesting that this ex vivo ap-
proach offers a reasonable assay system to model the in
vivo mechanism.
 
A Function-perturbing Antibody to MIG Blocks Monocyte
Binding to Inflamed HEV Ex Vivo.
 
The twofold increase
in WEHI 78/24 binding, although not profound, was con-
sistent, allowing us to test whether MIG plays a direct role
in monocyte adhesion at the surface of the HEVs. The
Stamper-Woodruff assay was performed on both normal
and inflamed lymph nodes (Fig. 5 B) in the presence of ei-
ther a MIG neutralizing antibody, control, or no antibody.
The control antibody had no effect on the induced WEHI
78/24 binding to inflamed HEVs; however, in the pres-
ence of a MIG-neutralizing antibody WEHI 78/24 bind-
ing was reduced to background binding levels. These re-
sults suggest that MIG may directly mediate monocyte
adhesion to HEVs but do not eliminate the potential for
additional mechanisms.
 
A Subset of Monocytes Expresses CXCR3.
 
CXCR3 is
the only known receptor for MIG. We asked whether a
CXCR3
 
 
 
 population of monocytes could be found in cir-
culating blood. It is extremely difficult to obtain circulating
monocytes from the mouse; therefore, the CXCR3 ex-
pression of human blood monocytes was analyzed by flow
cytometry. A small population of blood monocytes (de-
fined as CD11c
 
 
 
CD14
 
 
 
CD4
 
 
 
CD8
 
 
 
 mononuclear cells)
expressing CXCR3 was detected in two individual donors
(1.91 and 1.70%, respectively; two isotype-matched nega-
tive controls gave 0.12% and this background has been sub-
tracted). These results confirm those reported previously
(25) showing that CXCR3 was expressed on 1   1% of
normal peripheral blood monocytes and 8   4% of periph-
eral blood monocytes from patients with rheumatoid ar-
thritis. An interesting population of “plasmacytoid mono-
Figure 5. MIG may play a direct role in monocyte-selective recruit-
ment in inflammation. (A) Frozen lymph node sections were incubated
with cells under nonstatic, cold conditions, and the ability of the HEVs to
bind WEHI 78/24 was quantitated. Data is expressed as WEHI binding
relative to an internal standard. Lymph nodes from inflamed (black bars)
wild-type mice had a twofold increase in WEHI 78/24 binding to HEVs
when compared to mice that were not inflamed (white bar; P value  
0.01). Furthermore, monocyte binding to inflamed HEVs from TNF null
mice was similar to that observed in uninflamed wild-type mice, analo-
gous to what was observed in vivo. This experiment was repeated three
times. (B) The ex vivo assay described previously was performed on both
inflamed lymph nodes (black bars) or lymph nodes that were not inflamed
(white bars) in the presence of either a MIG neutralizing antibody (anti-
MIG), a control (Control Ab), or no antibody at all (No Ab). In the pres-
ence of the control antibody, there was approximately a twofold increase
in monocyte binding to inflamed HEVs compared to uninflamed HEVs
(P value   0.05). This was similar to that observed in the absence of anti-
body. In the presence of a MIG-neutralizing antibody, however, the de-
gree of monocyte binding to inflamed HEVs was reduced to background
levels. This experiment was repeated three times.1382 MIG Mediates Monocyte Binding to Inflamed Lymph Node HEV
cytes” that express CXCR3 (and L-selectin) has been
described in inflamed lymph nodes in and around the
HEVs (26). The relationship between these cells and the
subpopulation of peripheral blood CXCR3  monocytes is
not clear but could provide some insight on this specialized
cell lineage.
Together these data prompted us to ask whether newly
recruited monocytes express CXCR3. To obtain an en-
riched population of recruited monocytes, mice were in-
jected with thyoglycollate intraperitoneally and the elicited
cells were harvested by peritoneal lavage. Cells were
stained for CXCR3, CD11b, F4/80. and GR1 and ana-
lyzed by FACS®. As shown in Fig. 6, a significant percent-
age of the newly recruited monocytes express CXCR3, as
compared with the isotype control and GR1  neutrophils.
Discussion
Chemokines have emerged as an important class of mol-
ecules in directing selective recruitment of leukocyte sub-
sets to tissue microenvironments and sites of inflammation.
They, in conjunction with adhesion molecules, provide a
highly regulated and selective mechanism for recruitment
and microenvironmental localization of specific cell subsets
to tissues, and immune and inflammatory sites. We ob-
served previously that after induction of inflammation
there is a striking monocyte-selective increase in binding
to HEVs in inflamed lymph nodes (19) that could not be
explained solely by adhesion molecules known to play a
role in both monocyte and T cell recruitment. We used
this striking model of monocyte-selective recruitment
to test the hypothesis that monocyte chemoattractant
chemokines (such a MCP-1) might provide an additional
level of regulation in the specific recruitment of mono-
cytes upon inflammation. Surprisingly, MCP-1, a potent
monocyte chemoattractant shown to be key in recruit-
ment of monocytes in EAE and models of atherosclerosis,
was not displayed on the HEVs, but rather, was restricted
to the macrophage population (Fig. 3 A) and it is therefore
unlikely that MCP-1 can explain the monocyte-selective
recruitment observed.
Further immunohistochemical analysis revealed that a
subset of HEVs surrounding the B cell follicles (a subcom-
partment of lymph nodes) displayed the chemokine MIG.
Colocalization studies using confocal microscopy showed
that 6Ckine and MIG are colocalized in many perifollicular
HEVs while HEVs in the T cell zones express 6Ckine but
very little MIG. Interestingly, when the distribution of
anti-MIG antibody was assessed after intraveneous injec-
tion (followed by ex vivo staining for the presence of the
anti-MIG antibody as well as 6Ckine) the anti-MIG anti-
body was localized basolateral to that of the 6Ckine stain-
ing. It is not clear if the altered staining pattern reflects a re-
distribution of the injected antibody and/or the antigen
during the in vivo incubation period; however, it is inter-
esting to speculate that antigen distribution over time could
play a role in recruitment.
The subset of HEVs that support monocyte binding
were also perifollicular prompting us to test whether MIG,
a chemokine that has been shown to chemoattract acti-
vated T cells (for a review, see reference 27), might be in-
volved in monocyte recruitment to inflamed lymph nodes.
Indeed, the subset of HEVs that express MIG had a dra-
matically enriched capacity for binding monocytes com-
pared with MIG  HEVs. In vivo and ex vivo assays
showed that inflammation in TNF null mice failed to elicit
expression of MIG by HEVs and failed to elicit increased
monocyte recruitment via HEVs further strengthening the
correlation of MIG expression and monocyte recruitment.
More important was the demonstration that MIG neutral-
izing antibody was able to block inflammation-induced
monocyte binding and recruitment both in vitro and in
vivo, respectively. Together these data suggest that MIG
plays a key role in binding and recruitment of monocytes
to HEVs in lymph nodes draining a local inflammatory site.
The differential MIG expression patterns in wild-type
and TNF null mice revealed an interesting differential re-
quirement of TNF expression for MIG expression by
monocytes and HEVs. Recent studies suggest that TNF
expression is upstream of chemokine expression. For ex-
ample, Czermack et al. (20) showed that TNF neutralizing
antibodies reduced chemokine expression in a lung injury
model. In another study, TNF null mice had a decreased
expression of several chemokines, in particular BLC, in
the spleen (21). The downstream effect of the downregu-
lation of chemokine expression in these mice was the loss
of primary B cell follicular structure in the spleen, as well
Figure 6. Newly recruited monocytes express CXCR3.   Balb/C mice
were given a single intraperitoneal injection of thyoglycollate. 2 d later,
peritoneal cells were harvested and stained for CXCR3 or an isotype
control (CyC), CD11b (FITC), F4/80 (PE), and GR1 (APC). Gates
were set on newly recruited monocytes (CD11b ) and neutrophils
(GR1 ), after selection based on size and side-scatter. A significant per-
centage of monocytes recruited to the peritoneum expressed CXCR3
(compared to isotype control) whereas the neutrophil population did not.1383 Janatpour et al.
as in the lymph nodes (23, 28). At the message level, MIG
is expressed and upregulated upon inflammation in
TNF null mice; however, immunostaining revealed that
whereas wild-type mice had an increase of MIG  HEVs
of approximately sixfold with inflammation, inflamed
TNF null mice exhibited no such increase (data not
shown) and also revealed that MIG is predominantly ex-
pressed in macrophage-rich areas within the lymph node.
This suggests that low-level, basal expression of MIG is
TNF independent; however, the upregulation of MIG on
HEVs is TNF dependent.
Previous studies on MIG failed to show chemotaxis of
monocytes (29); however,  2% of circulating monocytes
express CXCR3, making this population difficult to detect
by calcium flux or chemotaxis assays. Selective recruitment
of this small population could result in reasonable accumu-
lation of cells to inflammatory sites. Interestingly, the per-
centage of CXCR3  monocytes is increased in peripheral
blood and synovial fluid monocytes in patients with rheu-
matoid arthritis (25) compared with normal controls. In-
deed, one study has shown the existence of a CXCR3 
population of “plasmacytoid monocytes” that are found in
and around inflamed lymph node HEVs (26). Here we also
showed that a high percentage of elicited peritoneal mono-
cyte/macrophages also express CXCR3. While the per-
centage of CXCR3  peripheral blood monocytes is small,
the frequency is increased in chronic inflammation and in
populations of recruited monocytes suggesting that selec-
tive expression of MIG by endothelium in inflammatory
sites could contribute to recruitment of a population of
monocytes expressing CXCR3.
Many recent studies have contributed to the strength of
the paradigm in which functionally distinct subsets of circu-
lating lymphocytes express unique sets of adhesion mole-
cules and chemokine receptors that allow them access to se-
lected tissues by virtue of tissue-specific expression of the
specific receptor ligands (adhesion molecules and chemo-
kines; for a review, see reference 30). The elegant studies of
Warnock et al. (18) revealed that the signaling molecules re-
quired to recruit lymphocyte subsets are differentially pre-
sented by HEVs in functionally distinct microdomains
within secondary lymphoid organs, suggesting that func-
tionally distinct microenvironments within a lymph node
can selectively recruit leukocyte subsets. We have provided
correlative and direct evidence that the lymph node mi-
croenvironment can direct the nature of molecules ex-
pressed on HEV subsets in a TNF-dependent fashion, that a
subset of predominantly perifollicular HEVs in lymph nodes
draining an inflammatory site express the CXC chemokine
MIG and that this subset of HEVs preferentially support the
monocyte-selective increase in adhesion induced by inflam-
mation. Future studies will determine whether other sites of
inflammation, particularly chronic inflammation, utilize
MIG in the recruitment of monocyte subpopulations.
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